? HEMATOLOGIC MALIGNANCIES AND CELLULAR THERAPIES PROGRAM The Hematologic Malignancies and Cellular Therapies Program (HMCT) is a multidisciplinary clinical, basic and translational research effort whose theme is to facilitate research with the ultimate objective to improve outcomes for patients with hematological malignancies. The broad, long-term goals of HMCT are to build on and extend current knowledge in the field of hematopoietic stem cell transplantation, immunotherapy and hematological malignancies, and to develop novel strategies for improving therapeutic results in patients with hematological malignancies through a collaborative and integrated approach involving the basic, translational and clinical investigators of HMCT. The HMCT has two focus areas related to our scientific aims and theme: 1) Understanding the interplay between hematopoietic/immune cells and their microenvironment with respect to immune activation and suppression; and 2) translating laboratory-based observations to clinical trials. Among the strengths of the program are the significant numbers of physician scientists working on fundamental problems in hematological malignancies and who are able to take the basic observations at the bench to the bedside through extensive collaborations with the clinical researchers. Specially, the scientific goals of the HMCT Program are: 1) To understand the role of the external environment and microenvironment in immune responses; 2) To elucidate the role of immune and stromal cells in anti-tumor responses and graft-vs.-host disease (GVHD); 3) To develop and execute investigator-initiated translational trials for hematologic malignancies - all with the goal to stimulate and facilitate intra- and inter-programmatic collaborations; 4) To further advance genomic signatures in hematological malignancies and evaluate the role of different signaling mechanisms and; 5) To train the next generation of MD, PhD, and M.D./Ph.D. students, postdoctoral, fellows, residents in the field of adult and pediatric hematopoietic stem cell transplantation, immunotherapy and hematological malignancies. The Program includes 36 primary and 9 secondary members from 6 departments and two schools within Duke University. Total direct funding for program members is $17.2M, of which $4.4M is peer-reviewed, including $1.6M from the NCI. From 2014- 2018, program members published 457 papers in peer-reviewed journals, 21% were intra-programmatic and 28% were inter-programmatic collaborations. During the current grant period, the program enrolled 1,519 subjects to all trials, 923 to interventional trials, and 587 to treatment trials.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Duke University
United States
Zip Code
Wu, Mengxi; Huang, Po-Hsun; Zhang, Rui et al. (2018) Circulating Tumor Cell Phenotyping via High-Throughput Acoustic Separation. Small 14:e1801131
Vlahovic, Gordana; Meadows, Kellen L; Hatch, Ace J et al. (2018) A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer. Oncologist 23:782-790
Xu, Yinghui; Liu, Hongliang; Liu, Shun et al. (2018) Genetic variant of IRAK2 in the toll-like receptor signaling pathway and survival of non-small cell lung cancer. Int J Cancer 143:2400-2408
Feng, Yun; Wang, Yanru; Liu, Hongliang et al. (2018) Novel genetic variants in the P38MAPK pathway gene ZAK and susceptibility to lung cancer. Mol Carcinog 57:216-224
Naqvi, Ibtehaj; Gunaratne, Ruwan; McDade, Jessica E et al. (2018) Polymer-Mediated Inhibition of Pro-invasive Nucleic Acid DAMPs and Microvesicles Limits Pancreatic Cancer Metastasis. Mol Ther 26:1020-1031
Wen, Juyi; Liu, Hongliang; Wang, Lili et al. (2018) Potentially Functional Variants of ATG16L2 Predict Radiation Pneumonitis and Outcomes in Patients with Non-Small Cell Lung Cancer after Definitive Radiotherapy. J Thorac Oncol 13:660-675
Li, Bo; Wang, Yanru; Xu, Yinghui et al. (2018) Genetic variants in RORA and DNMT1 associated with cutaneous melanoma survival. Int J Cancer 142:2303-2312
Gearhart-Serna, Larisa M; Jayasundara, Nishad; Tacam Jr, Moises et al. (2018) Assessing Cancer Risk Associated with Aquatic Polycyclic Aromatic Hydrocarbon Pollution Reveals Dietary Routes of Exposure and Vulnerable Populations. J Environ Public Health 2018:5610462
Bakthavatsalam, Subha; Sleeper, Mark L; Dharani, Azim et al. (2018) Leveraging ?-Glutamyl Transferase To Direct Cytotoxicity of Copper Dithiocarbamates against Prostate Cancer Cells. Angew Chem Int Ed Engl 57:12780-12784
Dai, Ziwei; Mentch, Samantha J; Gao, Xia et al. (2018) Methionine metabolism influences genomic architecture and gene expression through H3K4me3 peak width. Nat Commun 9:1955

Showing the most recent 10 out of 513 publications